Melanoma

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Binimetinib is a kinase inhibitor. The chemical name is 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. The molecular formula is C<span class="Sub">17</span>H<span class="Sub">15</span>BrF<span class="Sub">2</span>N<span class="Sub">4</span>O<span class="Sub">3</span> and the molecular weight is 441.2 daltons. The chemical structure of binimetinib is shown below:</p><div class="Figure"><a name="id1395"></a><img alt="Chemical Structure" src="mektovi-01.jpg"/></div><p>Binimetinib is a white to slightly yellow powder. In aqueous media, binimetinib is slightly soluble at pH 1, very slightly soluble at pH 2, and practically insoluble at pH 4.5 and higher.</p><p>MEKTOVI (binimetinib) tablets for oral use contain 15 mg of binimetinib with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate (vegetable source), and colloidal silicon dioxide. The coating contains polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide.</p></section>

MEKTOVI

binimetinib

binimetinib 15 MG Oral Tablet

Mektovi

binimetinib 15 MG Oral Tablet [Mektovi]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information - Braftovi

Medication Guide - Braftovi 

Mektovi - Prescribing Information 

Medication Guide - Mektovi 

Submit MSL Request 

Pharmacy List 

Reimbursement Information 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Formulary Exception Letter 

Other HCP Resources - Access 

Pfizer Oncology Together Form 

Pfizer Oncology Together Form - Spanish

Enroll in Patient Savings Program 

Pfizer Patient Assistance Program 

Free 90-day Supply: For Uninsured Patients While Applying for Medicaid

HCP Office : Attest & Print Co-Pay Card 

Pfizer Oncology Patient Access Guide 

Pfizer Oncology Patient Access Guide - Spanish 

Online Sample Form 

About Braftovi+Mektovi

Taking Braftovi+Mektovi

Side Effects 

Patient Resources 

Instructions For Use: Unresectable or Metastatic Melanoma With a BRAF V600E/K mutation

PA Checklist 

Appeals Checklist

Other HCP Resources 